Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic collaboration with Elligo Health Research. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-876-9300
Debt
Current Ratio0.97
Quick Ratio0.97
Price-To-Earnings
Sales & Book Value
Annual Sales$2.67 billion
Price / Sales1.85
Price / Cash Flow12.56
Price / Book1.66
Profitability
Net Income$-138,460,000.00
Net Margins-0.84%
Return on Assets3.47%
Miscellaneous
Employees21,000
OptionableOptionable
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health Inc (NASDAQ:SYNH) announced its earnings results on Tuesday, November, 6th. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.17. The company earned $1.11 billion during the quarter, compared to the consensus estimate of $1.12 billion. Syneos Health had a positive return on equity of 8.67% and a negative net margin of 0.84%. The firm's quarterly revenue was up 88.3% compared to the same quarter last year. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $2.66-2.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.70. The company issued revenue guidance of $4.375-4.435 billion, compared to the consensus revenue estimate of $4.45 billion.Syneos Health also updated its FY 2018 guidance to EPS.
What price target have analysts set for SYNH?
10 analysts have issued 12 month price targets for Syneos Health's shares. Their predictions range from $45.00 to $60.00. On average, they expect Syneos Health's share price to reach $54.75 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Price Targets for Syneos Health.
What is the consensus analysts' recommendation for Syneos Health?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.
Has Syneos Health been receiving favorable news coverage?
News articles about SYNH stock have been trending somewhat positive on Tuesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syneos Health earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Senomyx (SNMX), Dyadic International (DYAI) and BIOQUAL (BIOQ).
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair MacDonald, CEO & Director (Age 48)
- Dr. Michael Gibertini, Pres of Clinical Devel. for Therapeutic Bus. Units (Age 60)
- Mr. Michael Adam Bell, Consultant (Age 62)
- Mr. Jason M. Meggs, Chief Financial Officer (Age 42)
- Dr. Judith Ng-Cashin, Chief Scientific Officer
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Retirement Systems of Alabama (0.26%), Louisiana State Employees Retirement System (0.02%), National Investment Services Inc. WI (0.01%) and First Hawaiian Bank (0.01%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, Gregory S Rush, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.
Which major investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including National Investment Services Inc. WI and Louisiana State Employees Retirement System. Company insiders that have sold Syneos Health company stock in the last year include Christopher L Gaenzle and H Lee Equity Fund Vi Thomas. View Insider Buying and Selling for Syneos Health.
Which major investors are buying Syneos Health stock?
SYNH stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama and First Hawaiian Bank. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $48.01.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $4.90 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.
What is Syneos Health's official website?
How can I contact Syneos Health?
Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
